Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.

Experimental cell research - 1 Nov 2020

Fu Yige, Rathod Drishti, Patel Ketan

Abstract excerpt

Limited treatment options and development of resistance to targeted therapy within few months pose significant challenges in the treatment of BRAF-mutated malignant melanoma. Moreover, extensive angiogenesis and vasculogenic mimicry promote the rapid progression of disease. The purpose of this study was to develop a protein kinase C inhibitor anchored BRD4 PROTAC (ARV) loaded PEGylated nanoliposomes (LARPC)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Human Umbilical Vein Endothelial Cells
Share to Liposomes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanocytes

Share to Neovascularization, Pathologic

Share to Polyethylene Glycols

Share to Protein Kinase C

Share to Static Electricity

Share to Vemurafenib

Source

Identifiers

PMID: 32898554
DOI: 10.1016/j.yexcr.2020.112275

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.PMID 32898554Read ↗

Extracellular vesicle-mediated gene therapy targets BRAFV600E-mutant colorectal cancer by inhibiting the MEK1/2-ERK1/2 pathwaySemantic proximity Read ↗

In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.Semantic proximity Read ↗

Large extracellular vesicles regulate endothelial angiogenic potential via paracrine and autocrine signalingSemantic proximity Read ↗

ERK and mTORC1 Inhibitors Enhance the Anti-Cancer Capacity of the Octpep-1 Venom-Derived Peptide in Melanoma BRAF(V600E) Mutations.Semantic proximity Read ↗

BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.Semantic proximity Read ↗

Harnessing the polyamine transport system to treat BRAF inhibitor-resistant melanoma.Semantic proximity Read ↗

Overcoming Chemoresistance to Vemurafenib in Melanoma via Targeted Inhibition of PCK1 Using 3-mercaptopropionic AcidSemantic proximity Read ↗

Innovative platelet-derived extracellular vesicle drug delivery system for the treatment of corneal neovascularizationSemantic proximity Read ↗

Remodeling tumor microenvironment by liposomal co-delivery of DMXAA and simvastatin inhibits malignant melanoma progressionSemantic proximity Read ↗

Active Liposomal Targeting for Head and Neck Squamous Cell Carcinoma TreatmentSemantic proximity Read ↗

Tracking of Glycans Structure and Metallomics Profiles in BRAF Mutated Melanoma Cells Treated with Vemurafenib.Semantic proximity Read ↗

Ultrasound-propelled liposome circumvention and siRNA silencing reverse BRAF mutation-arised cancer resistance to trametinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.